Niagen Bioscience Inc (NAGE) Stock AnalysisNAGEStock AnalysisNiagen Bioscience Inc

Niagen Bioscience, Inc. is a global bioscience company promoting healthy aging. Its segments include Consumer Products, Ingredients segment, Analytical Reference Standards and Services and Pharmaceuticals. The Consumer Products segment provides finished dietary supplement products that contain its proprietary ingredient, Niagen directly to consumers and distributors. The Ingredients segment develops and commercializes proprietary-based ingredient technologies, including food-grade Niagen and pharmaceutical-grade Niagen, and supplies these ingredients as raw materials to the manufacturers of consumer products and outsourcing facilities. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services. The Pharmaceutical segment comprises pharmaceutical development of its proprietary molecules for potential therapeutic applications in rare diseases and conducts research and development activities. It operates in the Healthcare sector.

Niagen Bioscience, Inc. appears to be a good buy right now due to its current price of $3.29, which is significantly lower than the analyst price target of $10, suggesting a potential upside of over 200%. Additionally, the company has a strong gross margin of 64.84% and a recent RSI of 63.87, indicating positive momentum. However, the main risk is the recent decline in revenue, with a year-to-date change of -47.36%.